Anti-CGRP Antibodies: Real-World Impact on Migraines

Research Summary

A study published in Neurology and Therapy examined the real-world use of anti-CGRP monoclonal antibodies for migraine prevention in a large U.S. healthcare network. Out of 4683 eligible migraine patients, 484 completed a survey. Most respondents were women aged 30-54, with the majority experiencing 1-10 headache days monthly and moderate to severe disability. Of those using anti-CGRP treatments, 74% continued their medication for 6 months, and 55% for 12 months. Patients currently using these treatments reported significant improvements in headache reduction, functionality, and quality of life compared to past users, highlighting higher satisfaction levels with ongoing use.

Study Details

📄 Title: Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.

👥 Research Team: Buse DC et al.

📚 Published In: Neurol Ther

📅 Publication Date: 2025 Dec 17

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.